The US Meals and Drug Administration on Wednesday permitted a brand new weight problems tablet known as Foundayo. Taken as soon as each day, the tablet is made by pharmaceutical firm Eli Lilly, which additionally manufactures the favored weight-loss injection Zepbound.
Foundayo is a sort of remedy referred to as a GLP-1, a class that features rivals Ozempic and Wegovy. These medicine mimic a naturally occurring hormone within the physique that regulates blood sugar, slows digestion, and alerts a way of fullness to the mind.
It’s now the second GLP-1 tablet for weight reduction in the marketplace. In December, Novo Nordisk obtained FDA approval for its tablet type of Wegovy. The corporate’s unique model of Wegovy is a weekly injectable. Whereas the Wegovy tablet should be taken on an empty abdomen within the morning, Lilly says Foundayo may be taken any time of day with out meals or water restrictions.
With injectable GLP-1 medicine in excessive demand, pharma firms have been racing to develop weight-loss drugs, which could possibly be preferable for some sufferers and will doubtlessly develop the marketplace for GLP-1s. Drugs are additionally simpler to fabricate than injectable drugs, which might assist preserve continuous entry for sufferers. GLP-1 drugs have been in extreme scarcity from late 2022 by early 2025 as a result of demand outstripped manufacturing capability.
“Past provide and affordability, one of many larger obstacles to adoption has been that some sufferers simply do not need to take an injection,” says Ken Custer, govt vice chairman of Eli Lilly. “That could possibly be as a result of it is a needle, but it surely additionally may be that for them, an injection signifies that their situation is extra extreme than they really feel it’s at that time. For sufferers trying to get began with their weight administration journey, possibly a tablet is a neater place for them to begin.”
Like injectable GLP-1s, Foundayo begins at a low dose and is progressively elevated to attenuate nausea, vomiting, and diarrhea that may include these medicine.
In a medical trial, people taking the very best dose of Foundayo over 18 months misplaced a median of 27 kilos, or 12.4 % of their physique weight over 18 months. These taking a placebo misplaced simply 2 kilos, or lower than 1 % of their physique weight, over the identical time. Lilly’s tirzepatide, the energetic ingredient in its injectables Mounjaro and Zepbound, has proven a greater than 20 % discount in weight.
For Novo Nordisk’s Wegovy tablet, research contributors achieved a median weight lack of 13.6 % by 16 months. There have been no head-to-head trials evaluating the efficacy of Foundayo and the Wegovy tablet.
Eli Lilly did run a research to search out out what occurs when folks change from an injectable GLP-1 drug to Foundayo and located that it helped folks preserve most of their weight reduction. Those that switched to the tablet from injectable Wegovy regained a median distinction of two kilos, whereas those that switched to Foundayo from Zepbound gained a median of 11 kilos. The energetic ingredient in Foundayo, orforglipron, can be being studied as a possible therapy for kind 2 diabetes, obstructive sleep apnea, osteoarthritis knee ache, and different circumstances.
Foundayo is now accessible through the direct-to-consumer platform LillyDirect, with delivery starting April 6. Eli Lilly says Foundayo might be accessible extra broadly throughout US retail pharmacies and telehealth suppliers shortly after that. The tablet was included in a November 2025 deal to be supplied by the TrumpRx platform.
In its announcement on Wednesday, the FDA stated it reviewed Foundayo in simply 50 days as a part of a brand new pilot program meant to expedite approvals for medicine that align with nationwide well being priorities. New drug approvals sometimes take six to 10 months.
